Pleasanton, CA, United States of America

Byoung Kwon Chun



 

Average Co-Inventor Count = 9.0

ph-index = 5

Forward Citations = 174(Granted Patents)


Company Filing History:


Years Active: 2017-2022

Loading Chart...
Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: Innovations by Byoung Kwon Chun in Viral Treatment

Introduction

Byoung Kwon Chun is an accomplished inventor based in Pleasanton, CA, recognized for his significant contributions to the field of virology. With a total of five patents to his name, Chun has dedicated his career to advancing methods for treating viral infections, particularly those caused by the Filoviridae family of viruses.

Latest Patents

Chun's latest innovations include methods and pharmaceutical compositions aimed at treating infections from viruses such as the Marburg virus, Ebola virus, and Cueva virus. These patents focus on the use of ribosides, riboside phosphates, and their prodrugs, demonstrating a comprehensive approach to combating these life-threatening infections.

Career Highlights

Currently, Byoung Kwon Chun works at Gilead Sciences, Inc., a company renowned for its innovative contributions to health and pharmaceuticals. His work has positioned him as a valuable inventor within the company, furthering the development of antiviral therapies.

Collaborations

Throughout his career, Chun has collaborated with notable colleagues, including Edward Doerffler and Hon Chung Hui. Together, they have worked on projects that underscore the importance of teamwork in the innovation process, particularly in the challenging landscape of medical research.

Conclusion

Byoung Kwon Chun exemplifies the spirit of innovation in addressing pressing health challenges. His dedication to developing effective treatment methods for severe viral infections not only highlights his inventiveness but also places him at the forefront of biomedical advancements. As he continues to work with leading professionals in the field, Chun's contributions will likely lead to improved outcomes for patients affected by these dangerous viruses.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…